A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Phase of Trial: Phase I/II
Latest Information Update: 03 May 2017
At a glance
- Drugs ONCOS 102 (Primary) ; Cisplatin; Pemetrexed
- Indications Mesothelioma
- Focus Adverse reactions
- Acronyms MESOS
- Sponsors Targovax
- 13 Dec 2016 Status changed from suspended to recruiting.
- 30 Sep 2016 Status changed from recruiting to suspended.
- 01 Jul 2016 According to a Targovax media release, the first patient has been dosed in this trial.